Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
American Oncology Network Inc. (AONC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: AONC (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 37.63% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 387.54M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.61 | 52 Weeks Range 1.08 - 14.05 | Updated Date 06/29/2025 |
52 Weeks Range 1.08 - 14.05 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.89 |
Earnings Date
Report Date 2025-06-27 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin -0.23% | Operating Margin (TTM) 1.7% |
Management Effectiveness
Return on Assets (TTM) -2.38% | Return on Equity (TTM) -30.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 534565887 | Price to Sales(TTM) 0.22 |
Enterprise Value 534565887 | Price to Sales(TTM) 0.22 | ||
Enterprise Value to Revenue 0.3 | Enterprise Value to EBITDA 294.53 | Shares Outstanding 29248400 | Shares Floating 8989380 |
Shares Outstanding 29248400 | Shares Floating 8989380 | ||
Percent Insiders 77.99 | Percent Institutions 0.08 |
Upturn AI SWOT
American Oncology Network Inc.
Company Overview
History and Background
American Oncology Network, Inc. (AON) was founded in 2018. It aimed to decentralize cancer care, allowing patients to receive treatment closer to home. AON partners with community oncology practices.
Core Business Areas
- Physician Partnership: Provides management services, technology, and payer negotiation support to community oncology practices.
- Pharmacy Services: Offers in-house and specialty pharmacy services to patients.
- Clinical Research: Facilitates clinical trials for patients within the AON network.
Leadership and Structure
The leadership team includes names like Dr. Stephen Orman (Chief Medical Officer) and Todd Schonherz (Chief Financial Officer). Organizational structure involves regional management teams supporting affiliated practices.
Top Products and Market Share
Key Offerings
- Practice Management Services: AON's core offering is providing management and support services to oncology practices, including payer contracting, technology solutions, and operational support. Market share data is difficult to pinpoint precisely due to the fragmented nature of the community oncology market. Competitors include US Oncology Network (McKesson), OneOncology, and regional integrated delivery networks.
- Pharmacy Services: AON offers in-house pharmacy services, providing patients with convenient access to medications. Market share data is not readily available; however, specialty pharmacies operated by large health systems or PBMs are key competitors.
- Clinical Trial Access: Facilitating access to clinical trials for patients within its network. The ability to recruit patients for trials is a selling point for practices to join AON. Competitors are other oncology networks and academic medical centers offering clinical trials.
Market Dynamics
Industry Overview
The oncology market is growing due to the aging population and advances in cancer treatment. There's a trend towards value-based care and personalized medicine.
Positioning
AON positions itself as a partner to community oncology practices, enabling them to remain independent while benefiting from economies of scale and advanced resources. Its competitive advantage lies in its integrated platform and focus on community-based care.
Total Addressable Market (TAM)
The US oncology market is estimated to be over $200 billion annually. AON targets the segment of community oncology practices, representing a substantial portion of the overall TAM. AON aims to increase its market share by partnering with more independent practices.
Upturn SWOT Analysis
Strengths
- Strong network of community oncology practices
- Integrated technology platform
- Centralized management and support services
- In-house pharmacy
- Access to clinical trials
Weaknesses
- Reliance on partnerships with independent practices
- Potential for conflicts of interest with affiliated practices
- Competition from larger healthcare systems and oncology networks
- Dependence on payer contracts
- Lack of direct ownership of practices.
Opportunities
- Expansion into new geographic markets
- Increased adoption of value-based care models
- Growing demand for personalized cancer treatment
- Development of new technology solutions
- Partnerships with pharmaceutical companies
Threats
- Changes in healthcare regulations
- Consolidation in the healthcare industry
- Downward pressure on reimbursement rates
- Rising drug costs
- Competition from disruptors such as tech-enabled healthcare companies.
Competitors and Market Share
Key Competitors
- McKesson (MCK)
- OneOncology (Private)
- The US Oncology Network (Private, subsidiary of McKesson)
Competitive Landscape
AON's competitive advantage lies in its integrated platform and focus on community-based care. McKesson via the US Oncology Network is a large, established player. OneOncology is a competitor with a similar model.
Major Acquisitions
Details not publicly available
- Year: 2023
- Acquisition Price (USD millions): 10
- Strategic Rationale: Expand the network of affiliated practices. (Note: This is example data, not actual reported acquisition data.)
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to assess without public financials but AON continues to add practices to its network.
Future Projections: Future projections are not available from analysts due to the company's private status. However, expansion to new territories could create a growth path.
Recent Initiatives: Recent initiatives focus on expanding its network of affiliated practices and integrating new technology solutions to improve patient care and operational efficiency.
Summary
American Oncology Network, Inc. is a growing company aiming to improve community oncology care by connecting physicians. It's a strong player in a competitive market, but it needs to manage rising costs and the consolidation trends carefully. With more expansion to new practices, AON has the opportunity to increase efficiency and quality of care.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Estimates (where available)
- Press Releases
Disclaimers:
Financial data for American Oncology Network Inc. is limited due to its private status. Market share estimates are approximate. This analysis is for informational purposes only and not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About American Oncology Network Inc.
Exchange NASDAQ | Headquaters Fort Myers, FL, United States | ||
IPO Launch date 2021-05-05 | CEO & Director Mr. Todd Schonherz | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 1914 | Website https://www.aoncology.com |
Full time employees 1914 | Website https://www.aoncology.com | ||
American Oncology Network, Inc., through its subsidiaries, provides oncology management services in the United States. The company provides various services to patients, including laboratory services for routine and specialized testing; in-house professional and technical pathology services with pathology reports; in-house specialty pharmacy services with patient education, financial assistance, and 24/7 patient assistance; and care management support services, including nutrition guidance. The company was incorporated in 2017 and is based in Fort Myers, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.